Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: Comparison with other breast cancer subtypes

European Radiology

Volumn 22, Issue 8, 2012, Pages 1724-1734

  Youk, Ji Hyun ^a   Son, Eun Ju ^a   Chung, Jin ^a   Kim, Jeong Ah ^a   Kim, Eun Kyung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Breast; Contrast enhanced imaging; Diffusion weighted imaging; MRI; Triple negative breast cancer

Indexed keywords

BONO I; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GADOLINIUM PENTETATE MEGLUMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CARCINOMA; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; MUCINOUS CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TRIPLE NEGATIVE INVASIVE BREAST CANCER; TUBULAR CARCINOMA; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CONTRAST MEDIA; DIFFUSION; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; KINETICS; MAGNETIC RESONANCE IMAGING; MEDICAL ONCOLOGY; MIDDLE AGED; NECROSIS; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES;

EID: 84864683321     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-012-2425-2     Document Type: Article

References (42)

1. Yamamoto Y, Iwase H (2010) Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 15:341-351
2. de Ronde JJ, Hannemann J, Halfwerk H et al (2010) Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119:119-126
3. Denley H, Pinder SE, Elston CW, Lee AH, Ellis IO (2001) Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 54:20-24
4. Montagna E, Bagnardi V, Rotmensz N et al (2011) Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. Breast Cancer Res Treat 129:867-875
5. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874
6. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
7. Li SP, Padhani AR, Taylor NJ et al (2011) Vascular characterisation of triple negative breast carcinomas using dynamic MRI. Eur Radiol 21:1364-1373
8. van de Vijver MJ, He YD, van't Veer LJ et al (2002) A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
9. Desmedt C, Haibe-Kains B, Wirapati P et al (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165
10. Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E et al (2008) Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol 10:646-653
11. Elsawaf Z, Sinn HP (2011) Triple-negative breast cancer: clinical and histological correlations. Breast Care (Basel) 6:273-278
12. Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA (2010) Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol 20:1111-1117
13. Dogan BE, Gonzalez-Angulo AM, Gilcrease M, Dryden MJ, Yang WT (2010) Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol 194:1160-1166
14. Yang WT, Dryden M, Broglio K et al (2008) Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 111:405-410
15. Whitman GJ, Albarracin CT, Gonzalez-Angulo AM (2011) Triplenegative breast cancer: what the radiologist needs to know. Semin Roentgenol 46:26-39
16. Chen JH, Agrawal G, Feig B et al (2007) Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol 18:2042-2043
17. Uematsu T, Kasami M, Yuen S (2009) Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 250:638-647
18. Podo F, Buydens LM, Degani H et al (2010) Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 4:209-229
19. Woodhams R, Kakita S, Hata H et al (2010) Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging -comparison with contrast-enhanced MR imaging and pathologic findings. Radiology 254:357-366
20. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168
21. Moeder CB, Giltnane JM, Harigopal M et al (2007) Quantitative justification of the change from 10 % to 30 % for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 25:5418-5425
22. American College of Radiology (2003) Breast imaging reporting and data system-magnetic resonance imaging. In: American College of Radiology (ed) Breast imaging reporting and data system, 4th edn. American College of Radiology, Reston, pp 1-114
23. Kuhl CK, Mielcareck P, Klaschik S et al (1999) Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211:101-110
24. Koh DM, Collins DJ, Orton MR (2011) Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol 196:1351-1361
25. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492-2502
26. Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434
27. Anders C, Carey LA (2008) Understanding and treating triplenegative breast cancer. Oncology (Williston Park) 22:1233-1239
28. Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M (2009) Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 20:1948-1952
29. Lorgis V, Algros MP, Villanueva C et al (2011) Discordance in early breast cancer for tumour grade, estrogen receptor, progesterone receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour. Breast 20:284-287
30. Tamaki K, Sasano H, Ishida T et al (2010) Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci 101:2074-2079
31. Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125:627-636
32. Pereira FP, Martins G, de Oliveira C, Rde V (2011) Diffusion magnetic resonance imaging of the breast. Magn Reson Imaging Clin N Am 19:95-110
33. Hamstra DA, Rehemtulla A, Ross BD (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104-4109
34. Tsushima Y, Takahashi-Taketomi A, Endo K (2009) Magnetic resonance (MR) differential diagnosis of breast tumors using apparent diffusion coefficient (ADC) on 1.5-T. J Magn Reson Imaging 30:249-255
35. Kim SH, Cha ES, Kim HS et al (2009) Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic factors. J Magn Reson Imaging 30:615-620
36. Guo Y, Cai YQ, Cai ZL et al (2002) Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging 16:172-178
37. Razek AA, Gaballa G, Denewer A, Nada N (2010) Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors. NMR Biomed 23:619-623
38. Costantini M, Belli P, Rinaldi P et al (2010) Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness. Clin Radiol 65:1005-1012
39. Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102-125
40. Park SH, Moon WK, Cho N et al (2010) Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 257:56-63
41. Jeh SK, Kim SH, Kim HS et al (2011) Correlation of the apparent diffusion coefficient value and dynamic magnetic resonance imaging findings with prognostic factors in invasive ductal carcinoma. J Magn Reson Imaging 33:102-109
42. Matsuoka A, Minato M, Harada M et al (2008) Comparison of 3.0-And 1.5-Tesla diffusion-weighted imaging in the visibility of breast cancer. Radiat Med 26:15-20